semaglutide cv outcomes 🔴Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of death/MI/stroke regardless of baseline CKD severity in participants soul trial oral semaglutide cardiovascular

The severity and duration of side effects may differ between individuals, but most cases resolve within four weeks of starting treatment

4-Nonylphenol (4-NP) is one of the potent micropollutants which are pervasive, due to its high bioconcentration factor, lipophilicity (octanolwater partition coefficient log Kow of 4-Nonylphenol is 4.48) 1 , nondegradable causes prolonged existence in the environment and via biomagnification, it reaches to the human population.4-NP has been reported as a potent endocrine-disrupting chemical, xenoestrogenic, and neurotoxicity

Individual Results: Individual results may vary

[Abstract]2025 Nov 25;44(12):116620

It further determined if cardiometabolic risk markers such as fasting glucose, glycosylated hemoglobin A1c (HbA1c), blood pressure, and lipid profile changed over 12 months of semaglutide use by group